

## ABBOTT CATALYST TRIAL

Clinical trial of atrial fibrillation patients comparing left atrial appendage occlusion therapy to non-vitamin K antagonist oral anticoagulants



# INTRODUCING THE CATALYST TRIAL

### A CLINICAL TRIAL FOR PATIENTS WITH NON-VALVULAR ATRIAL FIBRILLATION WHO ARE ELIGIBLE FOR ORAL ANTICOAGULANT THERAPY

The CATALYST Trial is studying the Amplatzer™ Amulet™ Left Atrial Appendage Occluder in patients with non-valvular atrial fibrillation who are either on a non-vitamin K antagonist oral anticoagulant (NOAC) blood thinner, or eligible to take a NOAC.

Approximately 2650 subjects will be studied at up to 150 medical centers worldwide. Subjects will be randomly selected to either receive NOAC therapy (continue NOAC if currently taking) or undergo implant of an Amulet Left Atrial Appendage Occluder.

The results of the CATALYST Trial will help determine if left atrial appendage occlusion is a reasonable alternative to NOAC therapy. Future patients eligible for NOAC therapy may be able to avoid life-long blood thinners and instead be protected from stroke following a one-time implant of an Amulet Left Atrial Appendage Occluder.

A qualified team of doctors will monitor the patients included in the CATALYST Trial. Study participants will play an important role in helping doctors evaluate left atrial appendage occlusion as an option for patients with non-valvular atrial fibrillation and who are eligible for NOAC therapy.

**CAUTION:** Investigational device. Limited by federal (U.S.) law to investigational use only.

**CAUTION:** This product is intended for use by or under the direction of a physician. Prior to use, reference the Instructions for Use, inside the product carton (when available) or at [eifu.abbottvascular.com](http://eifu.abbottvascular.com) or at [medical.abbott/manuals](http://medical.abbott/manuals) for more detailed information on Indications, Contraindications, Warnings, Precautions and Adverse Events.

Illustrations are artist's representations only and should not be considered as engineering drawings or photographs. Photo(s) on file at Abbott.

#### Abbott

3200 Lakeside Dr., Santa Clara, CA. 95054 USA, Tel: 1.800.227.9902  
[www.cardiovascular.abbott](http://www.cardiovascular.abbott)

™ Indicates a trademark of the Abbott group of companies.

‡ Indicates a third party trademark, which is property of its respective owner.

© 2019 Abbott. All Rights Reserved. CL1009304 Ver. A | Item approved for U.S. use only.

### WHO CAN PARTICIPATE IN THE CATALYST TRIAL COMPARING LEFT ATRIAL APPENDAGE OCCLUSION TO NOAC THERAPY?

Both men and women can participate.  
You may qualify if:

- You have been diagnosed with non-valvular atrial fibrillation and are at an increased risk for ischemic stroke
- Your doctor believes you are eligible for NOAC therapy
- You are willing and able to complete the study follow-up visits
- You are willing to receive an Amulet Left Atrial Appendage Occluder if randomized to that therapy

If you think you qualify and are interested in participating in this trial, please contact your healthcare provider.

